Vericel Corporation (FRA:ATQP)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.44B -24.8% |
| Revenue (ttm) | 253.33M +22.4% |
| Net Income | 18.61M +620.7% |
| EPS | 0.37 +711.0% |
| Shares Out | n/a |
| PE Ratio | 77.50 |
| Forward PE | 61.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 29.40 |
| Previous Close | 28.00 |
| Day's Range | 29.40 - 29.40 |
| 52-Week Range | 25.40 - 39.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic... [Read more]
Financial Performance
In 2025, Vericel's revenue was $276.26 million, an increase of 16.45% compared to the previous year's $237.22 million. Earnings were $16.52 million, an increase of 59.41%.
Financial numbers in USD Financial StatementsNews
Vericel price target raised to $70 from $64 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Vericel (VCEL) to $70 from $64 and keeps a Buy rating on the shares following the Q1 report.
Vericel reports Q1 EPS (12c), consensus (16c)
Reports Q1 revenue $68.4M, consensus $63.62M. Reports Q1 MACI revenue $56.4M, up from $46.3M last year. Reports Q1 burn care revenue up 91% vs. last year. “The Company delivered outstanding…
Vericel raises FY26 revenue guidance to $326M-$336M from $316M-$326M
Consensus $323.43M. The company also reaffirmed its FY26 profitability guidance of a gross margin of approximately 75% and an adjusted EBITDA margin of approximately 27%.
Vericel Earnings Call Transcript: Q1 2026
Record Q1 revenue and profit growth driven by MACI and Burn Care, with raised full-year guidance reflecting strong momentum and BARDA contract contributions. Expanded sales force and new manufacturing capacity support continued growth, while competitive and market conditions remain favorable.
Vericel Earnings release: Q1 2026
Vericel released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Vericel Slides: Q1 2026
Vericel has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Vericel Quarterly report: Q1 2026
Vericel has published its Q1 2026 quarterly earnings report on May 7, 2026.
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%
Vericel Transcript: AGM 2026
The meeting confirmed quorum, elected all board nominees, approved executive compensation, and ratified the auditor appointment. No shareholder proposals or questions were submitted during the session.
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co...
Vericel price target lowered to $42 from $48 at Truist
Truist lowered the firm’s price target on Vericel (VCEL) to $42 from $48 but keeps a Buy rating on the shares as part of a broader research note previewing Q1…
MediWound says Vericel awarded ten-year contract valued at up to $197M
MediWound (MDWD) announced that Vericel (VCEL), its exclusive distributor of NexoBrid in North America, has been awarded a ten-year contract valued at up to $197M by the U.S. Biomedical Advanced…
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year...
Vericel awarded Health and Human Services contract valued at $196.87M
Vericel (VCEL) has been awarded a contract by Health and Human Services with a total contract value of $196.87M. This acquisition will allow BARDA to support procurement of an FDA-approved…
Vericel Proxy statement: Proxy filing
Vericel filed a proxy statement on March 19, 2026, providing details for shareholder voting and corporate governance matters.
Vericel Proxy statement: Proxy filing
Vericel filed a proxy statement on March 19, 2026, providing details for shareholder voting and corporate governance matters.
Vericel Transcript: Leerink Global Healthcare Conference 2026
Strong Q4 and full-year growth were driven by MACI and burn care, with a 30% sales force expansion and the Arthro launch fueling commercial momentum. Guidance for 2026 is balanced, with continued focus on operational excellence, pipeline progress, and ex-U.S. expansion targeted for 2027.
Vericel Transcript: TD Cowen 46th Annual Health Care Conference
Advanced therapies for sports medicine and burn care drove strong 2024 results, with MACI and MACI Arthro fueling 20%+ growth and expanding market reach. New manufacturing capacity supports global expansion, while burn care and BARDA opportunities offer further upside.
Vericel announces U.S. FDA approval of new manufacturing facility
Vericel (VCEL) Corporation announced that the U.S. Food and Drug Administration, FDA, has granted approval for MACI commercial manufacturing at its state-of-the-art cell therapy manufacturing facility...
Vericel price target raised to $64 from $60 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Vericel (VCEL) to $64 from $60 and keeps a Buy rating on the shares following the Q4 report. The company’s 2026 revenue…
Vericel Earnings Call Transcript: Q4 2025
Record Q4 and full-year revenue and profit growth were driven by strong MACI performance, margin expansion, and successful sales force expansion. 2026 guidance projects continued double-digit growth, with new clinical initiatives and international expansion on track.
Vericel Annual report: Q4 2025
Vericel has published its Q4 2025 annual report on February 26, 2026.
Vericel Annual report: Q4 2025
Vericel has published its Q4 2025 annual report on February 26, 2026.
Vericel Earnings release: Q4 2025
Vericel released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Vericel Slides: Q4 2025
Vericel has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.